Clinical Trial

Efficacy Biomarkers of DAOIB for Dementia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This open-label clinical trial will enroll patients with aMCI or mild AD, and they will be treated with DAOIB for 24 weeks. We will assess the patients before entering the study, 8 weeks, 16 weeks, and end point (24 weeks) of the study, and measure blood NMDA and oxidative stress - related biomarkers every 8 weeks. We hypothesize that NMDA and oxidative stress - related biomarkers can predict the efficacy of DAOIB for patients with aMCI or mild AD.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-10-13; most recent amendment 2026-03-18.
Trial Details
NCT Number NCT05582161
Lead Sponsor Chang Gung Memorial Hospital
Conditions Dementia
Enrollment 123 participants
Start Date 2022-10-03
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-19